Omega-3 fatty acids: chemistry, origin and intake values

Omega-3 fatty acids are among the most widely studied nutrients. They are a chemical family rather than a single substance, and the members of this family differ in origin, in metabolism and in the research that exists on them. This article describes the chemistry, the natural sources, the industrial production of oils, the official intake reference values and the findings of large clinical trials.

What defines an omega-3 fatty acid

Fatty acids consist of a carbon chain with a carboxyl group at one end and a methyl group at the other. In polyunsaturated fatty acids, the chain carries several double bonds. The designation omega-3, also written n-3, states that the first double bond counted from the methyl end sits between the third and fourth carbon atom. This single structural feature defines the entire family.

Three members are relevant in nutrition:

  1. ALA (alpha-linolenic acid, 18:3 n-3): a plant fatty acid with 18 carbon atoms and three double bonds. It occurs in linseed, chia seed, hemp seed, walnuts and in oils such as linseed, rapeseed and camelina oil.
  2. EPA (eicosapentaenoic acid, 20:5 n-3): a long-chain fatty acid with 20 carbon atoms and five double bonds, found mainly in oily sea fish and in some microalgae.
  3. DHA (docosahexaenoic acid, 22:6 n-3): 22 carbon atoms, six double bonds. DHA is a major structural component of the phospholipids of neuronal membranes and of the photoreceptor outer segments in the retina.

ALA is classed as an essential fatty acid because human metabolism cannot introduce a double bond at the n-3 position and the compound must come from food. EPA and DHA can be formed from ALA by chain elongation and desaturation, but isotope studies in humans put the conversion rate for EPA in the single-digit percentage range and the rate for DHA below one percent, with differences between men and women. This is the reason the two long-chain fatty acids are usually looked at separately from ALA.

Where the long-chain fatty acids come from

EPA and DHA are formed at the start of the marine food chain by microalgae such as Schizochytrium and Nannochloropsis. Zooplankton feed on these algae, fish feed on the zooplankton, and the fatty acids accumulate in the fat tissue of species such as salmon, mackerel, herring, sardine and anchovy. Fish do not produce these fatty acids themselves in relevant amounts; the content of farmed fish depends on what the feed contains.

How supplements are produced

Two production routes dominate the market.

Fish oil. The oil is obtained from whole fish, from by-products of fish processing or from the liver of certain species, as in cod liver oil. Production comprises several steps:

  1. Extraction: the raw material is cooked, pressed and separated; the crude oil is drawn off.
  2. Refining: degumming, neutralisation, bleaching and deodorisation remove free fatty acids, pigments and odour compounds.
  3. Purification: molecular distillation under vacuum removes contaminants such as dioxins, polychlorinated biphenyls and heavy metals; activated carbon treatment is also used.
  4. Concentration: transesterification converts the triglycerides into ethyl esters, which are then separated by distillation or urea complexation so that the EPA and DHA share rises. Many manufacturers re-esterify the concentrate into triglycerides afterwards.

Algal oil. Heterotrophic microalgae are cultivated in closed fermenters on a carbohydrate substrate, harvested and the oil extracted. The route avoids the marine food chain, which is why the product contains no fish protein and is suitable for vegan diets; contaminant levels are determined by the controlled culture conditions.

Chemical forms

  • Natural triglycerides: the form found in fish and algae, with three fatty acids esterified to glycerol.
  • Ethyl esters: the intermediate of the concentration process; some products are sold in this form. Absorption studies describe a greater dependence on the fat content of the accompanying meal than for triglycerides.
  • Re-esterified triglycerides: ethyl esters converted back to triglycerides after concentration.
  • Phospholipids: krill oil contains a share of the fatty acids bound to phospholipids.
  • Free fatty acids: used in some prescription preparations.

Oxidation and quality criteria

The many double bonds make these oils sensitive to oxygen, light and heat. Oxidation produces peroxides and secondary products such as aldehydes, which are measured as the peroxide value, the anisidine value and the combined TOTOX value. Analyses of retail products have repeatedly found samples above the limits set by the voluntary GOED monograph. Protective measures used in practice are inert gas packaging, opaque containers, cool storage and the addition of tocopherols. Independent certification programmes such as IFOS publish batch analyses for contaminants and oxidation parameters.

Reference values for intake

These are the official reference values of the European Food Safety Authority, not recommendations from this text:

  • For adults, EFSA sets an adequate intake of 250 mg EPA plus DHA per day.
  • For ALA, EFSA gives an adequate intake of 0.5 percent of total energy intake.
  • During pregnancy and breastfeeding, EFSA states an additional 100 to 200 mg of DHA per day.
  • EFSA assessed supplemental intakes of EPA and DHA combined of up to 5 g per day and did not identify safety concerns for adults at that level.

Under Regulation (EU) No 432/2012, a number of claims are authorised in the EU for these fatty acids, including claims on the maintenance of normal heart function, normal brain function and normal vision, each tied to specified daily amounts and conditions of use.

Large clinical trials

Omega-3 fatty acids have been examined in some of the largest nutrition trials ever conducted. The results are reported here as study outcomes:

  • GISSI-Prevenzione (1999): about 11,300 participants after myocardial infarction received 1 g of omega-3 fatty acids daily; the authors reported a difference in a combined endpoint against the control group.
  • ASCEND (2018): 15,480 adults with diabetes received 1 g daily over an average of 7.4 years; the trial reported no difference from placebo in the primary vascular endpoint.
  • VITAL (2018): 25,871 participants received 840 mg of EPA and DHA daily over an average of 5.3 years; no difference from placebo was reported for the primary endpoints.
  • REDUCE-IT (2018): 8,179 participants with elevated triglycerides received 4 g of icosapent ethyl, a purified prescription EPA ethyl ester, daily; a difference in cardiovascular endpoints was reported. The product is a licensed medicine, not a food supplement, and the choice of mineral oil as placebo has been discussed critically.
  • STRENGTH (2020): 13,078 participants received 4 g of a carboxylic acid formulation of EPA and DHA; the trial was stopped early because no difference from the corn oil comparator was observed.

Reviews that place these trials side by side point out that results differ by preparation, dose, comparator and population, and that findings for one product cannot be transferred to another.

Safety data and interactions

  • Commonly reported effects are belching with a fishy aftertaste, nausea and loose stools.
  • An influence on platelet aggregation is described; an interaction with anticoagulant and antiplatelet medicines is discussed, and use should be clarified with a physician before planned surgery.
  • Cod liver oil contains vitamin A and vitamin D; the upper intake levels for these vitamins apply.
  • In pregnancy, official advice on avoiding predatory fish species with high mercury content applies to fish consumption.
  • Fish oil products are not suitable for people with fish or seafood allergy; algal oil contains no fish protein.